<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04666701</url>
  </required_header>
  <id_info>
    <org_study_id>EMS1319 - ESCÓCIA</org_study_id>
    <nct_id>NCT04666701</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Escócia Association in the Treatment of Acute Pain</brief_title>
  <official_title>National, Multicenter, Randomized, Double-blind, Triple-dummy, Phase II Clinical Trial to Evaluate the Efficacy and Safety of Escócia Association in the Treatment of Acute Pain</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>EMS</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>EMS</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the efficacy and safety of Escócia association in&#xD;
      adults with acute pain.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">November 2021</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Anticipated">December 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline in pain intensity</measure>
    <time_frame>0-1 hour</time_frame>
    <description>The change from baseline in pain intensity 1 hour after using the first dose of medication. Pain intensity will be assessed by visual analog scale (VAS), between 0 cm (no pain) and 10 cm (worst pain), recorded in the participant's diary.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence and severity of adverse events recorded during the study</measure>
    <time_frame>10 days</time_frame>
    <description>Incidence and severity of adverse events recorded during the study over 10 days.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">99</enrollment>
  <condition>Acute Pain</condition>
  <arm_group>
    <arm_group_label>Escócia association</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The study is triple-dummy. The patient must take 3 pills, with a minimum interval of 6/6 hours for a maximum of 5 days, if pain, as follows:&#xD;
1 tablet Escócia association, oral&#xD;
1 dragee Placebo Scopolamine, oral&#xD;
1 tablet Placebo Ketorolac, sublingual</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ketorolac</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The study is triple-dummy. The patient must take 3 pills, with a minimum interval of 6/6 hours for a maximum of 5 days, if pain, as follows:&#xD;
1 tablet Ketorolac, sublingual&#xD;
1 tablet Placebo Escócia association, oral&#xD;
1 dragee Placebo Scopolamine, oral</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Scopolamine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The study is triple-dummy. The patient must take 3 pills, with a minimum interval of 6/6 hours for a maximum of 5 days, if pain, as follows:&#xD;
1 dragee Scopolamine, oral&#xD;
1 tablet Placebo Ketorolac, sublingual&#xD;
1 tablet Placebo Escócia association, oral</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Escócia association</intervention_name>
    <description>Escócia association tablet</description>
    <arm_group_label>Escócia association</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo Ketorolac</intervention_name>
    <description>Placebo Ketorolac tablet</description>
    <arm_group_label>Escócia association</arm_group_label>
    <arm_group_label>Scopolamine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo Scopolamine</intervention_name>
    <description>Placebo Scopolamine dragee</description>
    <arm_group_label>Escócia association</arm_group_label>
    <arm_group_label>Ketorolac</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ketorolac Tromethamine</intervention_name>
    <description>Ketorolac tablet</description>
    <arm_group_label>Ketorolac</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Scopolamine</intervention_name>
    <description>Scopolamine dragee</description>
    <arm_group_label>Scopolamine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo Escócia association</intervention_name>
    <description>Placebo Escócia association tablet</description>
    <arm_group_label>Ketorolac</arm_group_label>
    <arm_group_label>Scopolamine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Ability to confirm voluntary participation and agree to all trial purposes by signing&#xD;
             and dating the informed consent forms;&#xD;
&#xD;
          -  Participants, aged 18 years and older, with renal colic admitted in the emergency&#xD;
             service, or those who underwent an extracorporeal lithotripsy procedure to eliminate&#xD;
             kidney stones.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Known hypersensitivity to the formula components used during the clinical trial;&#xD;
&#xD;
          -  History of alcohol and/or substance abuse within 2 years;&#xD;
&#xD;
          -  Pregnant women, breastfeeding or planning to become pregnant, or women with the&#xD;
             potential to become pregnant who are not using a reliable method of contraception;&#xD;
&#xD;
          -  Participants weighing less than 50 kg;&#xD;
&#xD;
          -  Participants with suspected other causes of acute abdominal pain;&#xD;
&#xD;
          -  Participants with a known history of peptic ulcer, gastrointestinal bleeding,&#xD;
             perforation or inflammatory bowel disease;&#xD;
&#xD;
          -  Participants with hypovolemia or dehydration;&#xD;
&#xD;
          -  Renal failure, defined by the estimated glomerular filtration rate [eGFR] &lt;60 mL / min&#xD;
             / 1.73 m2;&#xD;
&#xD;
          -  Participants with a known medical history of cerebrovascular bleeding, hemorrhagic&#xD;
             diathesis (hemophilia), blood clotting disorders; postoperative of coronary artery&#xD;
             bypass graft surgery, or using anticoagulants, including low heparin dose (2500-5000&#xD;
             units every 12 hours);&#xD;
&#xD;
          -  Participants in the postoperative period with a high risk of bleeding or incomplete&#xD;
             homeostasis;&#xD;
&#xD;
          -  Participants with cardiovascular disease, chronic heart failure or with increased risk&#xD;
             of cardiovascular events are at the discretion of the investigator, in order to&#xD;
             include the participant;&#xD;
&#xD;
          -  Participants with a current medical history of cancer and / or cancer treatment in the&#xD;
             last 5 years;&#xD;
&#xD;
          -  Participants using pentoxifylline, probenecid or lithium salts;&#xD;
&#xD;
          -  Participants with megacolon and / or paralytic or obstructive ileus;&#xD;
&#xD;
          -  Participants with glaucoma and myasthenia gravis;&#xD;
&#xD;
          -  Participants on treatment with MAO inhibitors, or participants who have been treated&#xD;
             with these drugs within 14 days;&#xD;
&#xD;
          -  Participants on epilepsy not adequately controlled treatment.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Monalisa FB o, MD</last_name>
    <phone>+551938879851</phone>
    <email>pesquisa.clinica@ncfarma.com.br</email>
  </overall_contact>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>December 8, 2020</study_first_submitted>
  <study_first_submitted_qc>December 8, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 14, 2020</study_first_posted>
  <last_update_submitted>December 8, 2020</last_update_submitted>
  <last_update_submitted_qc>December 8, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 14, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acute Pain</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ketorolac</mesh_term>
    <mesh_term>Ketorolac Tromethamine</mesh_term>
    <mesh_term>Scopolamine</mesh_term>
    <mesh_term>Butylscopolammonium Bromide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

